CD4 and COVID-19: Our results add to a growing body of evidence that adult PLWH receiving stable antiretroviral therapy, who have suppressed plasma HIV loads and who have CD4+ T-cell counts in a healthy range, generally mount robust initial humoral immune responses to two COVID-19 vaccine doses10,33–35,37,38.